Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

48.34 -1.70 (-3.39%)
Streaming Delayed Price Updated: 11:59 AM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
86 87 Next >
Novo Nordisk Wins Another Legal Battle Against Compounding Of Wegovy, Ozempic: Retail’s Bullish
Steve Benz, legal and US general counsel of Novo Nordisk, said the company is “pleased” that the court rejected the compounders' attempts to “undermine” the FDA's decision that the shortages of Wegovy... 
Via Stocktwits
Topics Lawsuit
Why Novo Nordisk Stock Dropped Today
Ignore the noise. Novo Nordisk stock is a bargain. 
Via The Motley Fool
Top 2 Health Care Stocks That May Crash This Month
 
Via Benzinga
Viking Therapeutics Stock May Struggle After As-Expected Report
Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard. 
Via MarketBeat
The Best Stock to Buy With Less Than $60 in the Market Sell-Off
Via The Motley Fool
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
Via Benzinga
Topics Government
Eli Lilly Nails Oral GLP-1 Trial—Here’s What It Means for LLY
Take a deep dive into Eli Lilly's latest clinical GLP-1 results that sent shares soaring. The company has a big opportunity to serve needle-phobic patients. 
Via MarketBeat
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Via The Motley Fool
Is Eli Lilly Stock a Buy?
The competitive landscape for GLP-1 agonist weight loss drugs has undergone a significant shake-up. 
Via The Motley Fool
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for May 1. 
Via Benzinga
Why Novo Nordisk Stock Popped Today
Novo Nordisk has a GLP-1 Ozempic pill. That's both good and bad news for Novo Nordisk stock. 
Via The Motley Fool
Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop
Reports suggest Novo Nordisk has asked the FDA to approve its oral semaglutide, two years after reporting a Phase 3 win. 
Via Investor's Business Daily
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Down 60%, Is This Growth Stock Too Cheap to Ignore?
Via The Motley Fool
Novo Nordisk's FDA Submission For Obesity Pill Gets Retail Traders Buzzing Amid Fierce Eli Lilly Rivalry
The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed successful results. 
Via Stocktwits
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Via The Motley Fool
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
Via Benzinga
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today
Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations. 
Via Benzinga
Topics Government
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035. 
Via Benzinga
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Analyst downgrades Novo Nordisk, citing Eli Lilly's rising dominance and weak competitive outlook for 2025. 
Via Benzinga
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by... 
Via Benzinga
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
Mark Cuban Says This Trump Healthcare Order 'Could Save Hundreds Of Billions'
Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump's 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs)... 
Via Benzinga
Topics Government
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Eli Lilly’s Weight Loss Pill Succeeds In Phase 3 Trials On Type-2 Diabetes Patients
The company says orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete a Phase 3 trial. 
Via Stocktwits
Topics Economy Government Stocks
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
86 87 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.